Are active medical device combination products exempt from clinical evaluation?
In the field of medical devices, the speed of technological innovation and product iteration is increasing, with the emergence of a number of active medical device combination products. These products consist of multiple independent functional modules, each of which may have been widely recognized when used individually, but whether they can be similarly exempted from clinical evaluation in the combined state has become a focus of industry attention. We have compiled a list of conditions under which active medical device combination products can be exempted from clinical evaluation, as well as the key things applicants need to be aware of during the process. The content of this article is for reference only. For more information, please contact us by email or phone for a specific evaluation.
01 Pre-conditions for Clinical Evaluation Exemption
For active medical device combination products to be exempt from clinical evaluation, the following three core conditions must be met:
Independence of modules and catalog consistency: firstly, each independent module constituting the combination product must already be listed in the Catalog of Medical Devices Exempted from Clinical Evaluation, which means that these modules have been proven to be safe and effective when used individually without the need for additional clinical data support.
Proof of no interaction: Next, the applicant needs to provide sufficient evidence that the modules do not interact with each other when used in combination, i.e., the interaction between the modules will not change their respective safety and efficacy. This is critical because even seemingly independent modules may have unintended interactive effects under certain conditions.
Limitations on Clinical Use: Finally, the clinical use of the combined product cannot go beyond what is specified in the Catalog of Medical Devices Exempt from Clinical Evaluation. This means that the scenarios of use and expected effects of the product after combination should be consistent with the use of each module as described in the catalog.
02 Risk assessment and additional considerations
Even if the above conditions are met, the applicant is required to further assess additional risks that may be posed by the combination of modules. Although each module is recognized for its safety and effectiveness when used individually, new risk factors may arise when they are combined, for example:
System compatibility risk: Technical specifications and interface standards between different modules may not match exactly, leading to system-level compatibility issues.
User operation risk: Combined products may require higher operating procedures and skills from users, increasing the possibility of misuse.
Maintenance and fault risk: The complexity of multiple modules may lead to increased maintenance difficulties, and fault troubleshooting and repair become more difficult.
03 Application Process and Documentation Preparation
In order to successfully apply for exemption from clinical evaluation, the applicant needs to prepare a series of detailed documentation, including but not limited to:
Proof of module independence and catalog consistency: detailed description of the function and technical parameters of each module, as well as its position in the Catalog of Medical Devices Exempted from Clinical Evaluation.
Scientific proof of no mutual influence: through theoretical analysis, simulation test, laboratory validation and other methods, prove that there is no negative influence between modules.
Reasonable statement of clinical use: Elaborate the scope of clinical application of the combination product to ensure its consistency with the use specified in the catalog.
Risk assessment report: comprehensively analyze the new risks that may arise from the combination product and propose corresponding risk control measures.
04 Conclusions and Recommendations
Active medical device combination products can be exempted from clinical evaluation under certain conditions, but this does not mean that the application process will become easier. On the contrary, applicants need to put in more effort to ensure the safety, efficacy and compliance of the product combination. It is important to be meticulous in preparing the application materials, and not to overlook every aspect, from the independence of the modules to the risk assessment of the combination. At the same time, maintaining close communication with the regulator and obtaining timely guidance and feedback is crucial for successful approval.
By following the above guidelines, manufacturers of active medical device combinations can not only effectively reduce the burden of clinical evaluations, but also accelerate the pace of product launches, ultimately bringing more advanced and safer medical solutions to patients.
Beijing HMK specializes in NMPA registration/filing for medical devices, pharmaceuticals, cosmetics, and compliance services, and is committed to providing professional compliance solutions for companies. Please feel free to contact us!
